Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL.

Trial Profile

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Bendamustine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 14 May 2015 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2014 recruiting as reported by ClinicalTrials.gov.
    • 22 Jan 2015 According to the the ClinicalTrials.gov record, planned end date changed from 1 Mar 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top